Kornimate/medical-research-clean huggingface dataset:
trametinib combined with everolimus and lenvatinib for recurrent/refractory advanced solid tumors

Conditions: Solid Tumor, Adult; Hepatocellular Carcinoma

Summary: to study the clinical effect of trametinib combined with everolimus and lenvatinib in the treatment of recurrent/refractory advanced solid tumors.

the tumor diameter was measured and the efficacy was evaluated after treatment with trametinib combined with everolimus and lenvatinib.

Eligibility criteria:
inclusion criteria: * recurrent/refractory advanced solid tumors * age between 18 and 85 years * expected life expectancy is greater than three months exclusion criteria: * benign tumor * life expectancy is less than three months * serious medical commodities * others

Keywords: hepatocellular carcinoma;lung cancer trametinib everolimus lenvatinib
study of once-daily oral rgt001-075 compared with placebo in adults with obesity or are overweight with weight-related health conditions

Conditions: Obesity or Overweight

Summary: this is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of rgt001-075 in adults who are obese (bmi ≥30 kg/m²) or who are overweight (bmi ≥27 kg/m²) with at least one weight-related comorbidity. rgt001-075 or matching placebo will be administered once daily.


Eligibility criteria:
inclusion criteria: 1. male or female, age 18-75 years (inclusive) at the time of signing informed consent. 2. hemoglobin a1c (hba1c) \<6.5% at screening. 3. bmi ≥30 kg/m². 4. bmi ≥27 kg/m² and \<30 kg/m² with at least 1 weight-related comorbidity: * hypertension * dyslipidemia * cardiovascular (cv) disease * obstructive sleep apnea 5. have a stable body weight (\< 5% change) for the 3 months prior to randomization. exclusion criteria (obesity related): 1. have obesity induced by other endocrine disorders (for example, cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, melanocortin 4 receptor deficiency or prader-willi syndrome). 2. have a prior or planned surgical treatment for obesity. 3. have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months before screening such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal liner. 4. have been treated with prescribed or otc drugs or alternative remedies that promote weight loss within the last 3 months before screening. exclusion criteria (medical conditions) 1. diabetes. 2. have a history of acute or chronic pancreatitis. 3. have current symptomatic gallbladder disease or biliary disease. 4. have known liver disease other than masld. 5. have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2a or type 2b, thyroid c-cell hyperplasia, or medullary thyroid carcinoma (mtc). 6. have a serum calcitonin ≥20 pg/ml. 7. have an egfr \<30 ml/min/1.73 m², as determined by the central laboratory at screening. 8. have a history of major depressive disorder (mdd) or other severe psychiatric disorders (e.g., schizophrenia or bipolar disorder) within the last 2 years. 9. have had any exposure to glp-1 analogs, or other related compounds within the prior 3 months or any prior history of clinically significant side effects from glp-1 receptor agonist (glp-1 ra) or other related compounds containing glp-1.

Keywords: glp-1 receptor agonist (glp-1 ra) obesity
mesenchymal stem cell and islet co-transplantation

Conditions: Chronic Pancreatitis; Diabetes

Summary: the purpose of this study is to show safety and tolerability to our mesenchymal stromal cells (mscs) product which will be autologous in nature, expanded using a non-xenogeneic, human component expansion media (pooled human platelet lysate) and delivered fresh. subsequently, the investigators intend to test whether infusion of mscs immediately after islet autograft can reduce onset of diabetes and improve glycemic control after total pancreatectomy and islet autotransplantation.

this is a phase i study evaluating safety and tolerability of autologous bm-mscs in chronic pancreatitis patients who undergo total pancreatectomy and islet autotransplantation (tp-iat). cct-bmmsc will be infused at one of the following doses: (tier 1), 20x10\^6 cell per patient, (tier 2), 50x10\^6 cell per patient, and (tier 3), 100x10\^6 cell per patient. primary objective: to describe and compare the safety and tolerability of infusion of fresh autologous bone marrow-derived mesenchymal stromal cells after islet transplantation in chronic pancreatitis patients who undergo tp-iat. the investigators plan to enroll 24 patients for the whole study. the duration of this study is 12 months. the investigators anticipate that this study will be completed within 2 years of commencement. secondary objective: efficacy of infusion of fresh autologous bone marrow-derived mesenchymal stromal cells together after islet transplantation in chronic pancreatitis patients who undergo tp-iat as assessed through onset of diabetes, glycemic control, pain relief and quality of life index. safety variables: adverse events (aes), laboratory parameters (hematology, biochemistry, urinalysis), vital signs

Eligibility criteria:
inclusion criteria: * chronic pancreatitis patients who undergo tp-iat. * \>18 years of age. * patients with bmi from 18.5 to 30. * renal function: \>90mls/min/1.73m squared * normal inr/pt/ptt values for musc clinical laboratory standards * diabetes free before surgery (fasting blood glucose\<125mg/dl). * no prior pancreatic surgery with the exception of transduodenal sphincteroplasty or whipple/beger procedure. * patients with normal liver function as measured by serum levels of aminotransferase including alanine aminotransferase (alt), and aspartate aminotransferase (ast), and total bilirubin levels. exclusion criteria: * patients whose hemoglobin, hematocrit, and platelet count are above or below normal values for musc clinical laboratory standards. * patients who has hematological malignancy. * patients who are under immunosuppression. * patients with marked calcification disease on ct scan. * patients with severe fibrosis and atrophy on pancreas mri.
automated telephone reminder for colonoscopy

Conditions: Polyps

Summary: this is a quality improvement study to determine the impact of an automated telephone reminder on the quality of bowel preparation in patients undergoing outpatient colonoscopy.

randomized trial of automated reminders with bowel prep instructions and encouraging clear fluid ingestion. the phone calls will occur 48-96 hours prior to the scheduled colonoscopy. all patients undergoing outpatient colonoscopy and prescribed sodium picosulfate plus magnesium citrate will be eligible for enrollment.

Eligibility criteria:
inclusion criteria: * adult patients * scheduled for outpatient colonoscopy at a later date * prescribed evening-before or split-dose low volume preparation regimens exclusion criteria: * refusal to receive automated telephone reminder * no access to telephone * urgent/emergent indication for colonoscopy * prescribed a bowel prep other than pico-salax/purgodan * receiving upper and lower combined procedure
anterior segment and corneal parameters in keratoconus and high myopic astigmatism using schiempflug imaging

Conditions: Keratoconus; High Myopia

Summary: the purpose of this study was to compare scheimpflug corneal tomography findings in keratoconus and high myopic astigmatic eyes, as well as to establish the parameters distinguishing keratoconus from high myopic astigmatism.

keratoconus is a progressive, non-inflammatory corneal ecstatic disorder caused by alteration in the structure and organization of corneal collagen fibers. it results in uneven steepening of the cornea, resulting in irregular astigmatism that cannot be totally corrected with glasses, impairing the quality of life . however, in many cases, increased axial length adds to the myopic component of refractive error . thereafter, keratoconus patients frequently have axial high myopia with irregular astigmatism . furthermore, early diagnosis of keratoconus aids in the timely management of the condition, thus improving patients' quality of life. according to research, high myopia, in addition to the degree of astigmatism, is an alarming sign that requires further corneal assessment to rule out any corneal abnormalities such as keratoconus. furthermore, keratoconus could be misdiagnosed as meridional amblyopia attributable to myopic astigmatism due to the lack of corneal tomography measurements . as a result, it is critical to evaluate all high myopia patients, particularly those considering refractive surgery, for high-risk corneas. the criteria for diagnosing and classifying keratoconus are based on anterior corneal curvature data obtained using placido-based corneal topography . early alterations in eyes with keratoconus, however, have been found on the posterior corneal surface . scheimpflug imaging uses a revolving scheimpflug camera to determine the front and back surfaces of the cornea, hence measuring the overall thickness. several studies have utilized scheimpflug tomography to evaluate anterior segment parameters between normal eyes and eyes with keratoconus , but the utility of scheimpflug imaging to distinguish between keratoconus and high myopic astigmatism has not been thoroughly examined.

Eligibility criteria:
inclusion criteria: * keratoconus patient * virgin clear cornea with high myopic astigmatism * normal cornea with high myopic astigmatism exclusion criteria: * patients had previous ocular surgery * ocular diseases rather than keratoconus * contact lens wearer * corneal opacity and corneal dystrophy
a survey of adults and children with allergic rhinoconjunctivitis (mk-7243-021)

Conditions: Allergic Rhinoconjunctivitis

Summary: this study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.


Eligibility criteria:
inclusion criteria: * diagnosed with hay fever, rhinitis or nasal and/or eye allergies and display symptoms of sneezing, itching, watery eyes, nasal congestion, or other nasal or eye allergy symptoms over the past 12 months or take any medication for their hay fever, rhinitis, nasal or eye allergies * 5 years of age or older * have a telephone exclusion criteria: * if less than 18 years old and there is no adult available that is knowledgeable about the participant's health

Keywords: allergies immunotherapy
effects of inhibition techniques applied on trigger points of supraspinatus muscle on echogenicity and patients' pain

Conditions: Shoulder Pain

Summary: trigger points (tp) are described as "hard, palpable nodules located within the taut bands of skeletal muscle". the aim of this study is to evaluate the reproductibility of palpation of tp between osteopaths and to compare this perception to ultrasound measures of echogenicity. method: a sample of 61 patients will be included in the study. an osteopath will determine the eligibility of the study. the supraclavicular area will be mark every 2 cm to establish a grid for all evaluations. all included osteopaths will receive a formation to test and treat with the same approach and the same strength during all stages. first an osteopath will evaluate with palpation the presence of tp at every box of the grid. a second osteopath will evaluate the same boxes and will be blinded to the result of the first osteopath. at each step of palpation, a pain assessment will be carried out at each box. then, the ultrasound technician will evaluate the echogenicity of every box and will be blinded to the prior results. every patient with a tp diagnosed by the first osteopath, will be randomised into two groups (inhibition of trigger point technique with a long standing press on the tp, placebo technique with four light touch techniques on both shoulders, sternum and rachis). the second osteopath will evaluate the same boxes and will be blinded to the randomisation process. at each step of palpation, a pain assessment will be carried out at each box. the ultrasound technician will evaluate an other time the echogenicity of every box and will be blinded to the prior results, and randomisation. a blinded statistician will evaluate the efficacy of inhibition technique on echogenicity and patients' pain during the tests. the protocol has been approved by a french ethic committee.


Eligibility criteria:
inclusion criteria: * age between 18 and 50 years * be affiliated to a social security system or benefit from such a system. exclusion criteria: * pregnant or breast-feeding women * adults under guardianship * patients under protection * history of tegumentary or muscular damage in the area concerned * wish to stop the study

Keywords: trigger point osteopathic palpation ultrasound
study of artery conditions of 'at-risk' asian people not on lipid-lowering drugs

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to obtain the distribution of measurements of the intima media thickness of carotid arteries in people with high cardiovascular risk.


Eligibility criteria:
inclusion criteria: * provision of signed informed consent. * patients with at least two cvd risk factors but not on lipid-lowering agents exclusion criteria: * subjects with chd, any conditions that may affect hs-crp levels. * subjects on any lipid-lowering drug treatment within the last 3 months prior study entry.

Keywords: cardiovascular disease carotid intima media thickness
extensive prospective validation study of the nightowl home sleep apnea test

Conditions: Sleep Apnea

Summary: extensive prospective validation study of the nightowl, a type iv home sleep apnea test (hsat), compared to traditional psg and hsat monitors.

the purpose of this prospective validation study is the evaluation of the accuracy of the nightowl hsat to derive parameters relevant for the diagnosis of sleep apnea. the nightowl hsat comprises a finger or forehead mounted sensor and an automated analytics software. the sensor measures double-wavelength photo-plethysmography and accelerometry. the analytics software automatically interprets the sensor data and derives a measure of sympathetic activation of the autonomic nervous system, oxygen saturation, instantaneous pulse rate and activity. for each patient in the cohort, the ahi derived by the nightowl will be compared to that of the type i sleep monitor (in-lab psg), which will acquire data simultaneously during the diagnostic night of the patient referred to the sleep lab for a polysomnography. on a randomly selected subset of patients, a benchmark hsat will additionally be applied for comparison of its automated ahi derivation to that of the nightowl.

Eligibility criteria:
inclusion criteria: * indication for a sleep study exclusion criteria: * mentally disabled people
low-pressure pulmonary recruitment maneuver to decrease post-laparoscopic shoulder pain in gynecologic surgery

Conditions: Gynecologic Disease; Laparoscopic Surgery

Summary: research objective to compare outcomes (shoulder pain score, wound pain score, post-operative residual pneumoperitoneum, lung complication, gi discomfort, administered additional analgesics, time to hospital staying) of using pulmonary recruitment maneuver with pressure 30 cmh2o, 40 cm h2o and control group in women with post laparoscopic gynecologic surgery in rajavithi hospital.

research design is randomized control trial. the women who go to laparoscopic gynecologic surgery don't know the allocation. women will be randomizes in to 3 group: prm 30 cmh2o, 40 cmh2o and control after laparoscopic surgery has finished in operator room (before moving off trocar), woman all group will be set in trenderlenberg position (tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes. the patients in group of using pulmonary recruitment maneuver will be received positive pressure from balloon bag from anesthesiologist 5 times of setting pressure \[30 cmh2o, 40 cmh2o\], 5 seconds per time to increase indirect abdominal pressure to release residual gas after surgery at 12, 24 and 48 hours, patients will be follow up and evaluate shoulder and wound pain. chest x-ray will be done to evaluate residual pneumoperitoneum and lung complication. gi discomfort, administered additional analgesics and time to hospital staying will be evaluated and recorded.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * anesthesiologists physical status (asaps) classification i-ii * absence of pregnancy * with inform-consent exclusion criteria: * inability to accurately express pain * past history of shoulder or lung surgery * chronic shoulder problem * epigastric pain * lung disease such as emphysema or pneumothorax * severe kidney or liver disease * drug allergy (nsaids, paracetamol) * on current medication: corticosteroid * psychiatric disorder

Keywords: low pressure pulmonary recruitment maneuver post-laparoscopic shoulder pain
study of crenolanib with ramucirumab and paclitaxel for advanced esophagogastric adenocarcinoma

Conditions: Esophagogastric Adenocarcinoma

Summary: this is a single-arm phase i/ib study of crenolanib combined with ramucirumab/paclitaxel as second line therapy for patients with advanced/metastatic adenocarcinoma of the esophagus, gej or stomach. patients will be enrolled in two phases; dose escalation phase and dose expansion phase.


Eligibility criteria:
inclusion criteria: * pathologically confirmed adenocarcinoma of the esophagus, gej or stomach. * stage iv disease or locally advanced/unresectable tumors * prior progression on only 1 line of chemotherapy in the advanced/metastatic setting containing a fluoropyrimidine and/or platinum compound * eastern cooperative oncology group (ecog) performance status of 0-1 exclusion criteria: * prior treatment with a taxane is not permitted in the dose-expansion phase. patients in the dose escalation component may have received a taxane in the peri-operative setting, provided they developed disease recurrence \>6 months after the completion of this therapy * known pre-existing liver disease (e.g. cirrhosis, chronic hepatitis b or c, nonalcoholic steatohepatitis, sclerosing cholangitis) * patients with any clinically apparent ascites or who have undergone a paracentesis within 7 days of enrollment * uncontrolled hypertension (systolic pressure \>140 mm hg or diastolic pressure \> 90 mm hg on repeated measurement) despite optimal medical management * active or clinically significant cardiac disease * patients with arterial thrombotic events, such as cerebrovascular accident or myocardial infarction, within 6 months of enrollment
branched-chain amino acids supplementation and resistance exercise-induced muscle damage and inflammation

Conditions: Muscle Damage; Inflammation

Summary: this study aims to evaluate the effects of branched-chain amino acids (bcaa) supplementation on resistance exercise-induced muscle damage and inflammation.


Eligibility criteria:
inclusion criteria: * sedentary; * no muscle disorders; * must be able to swallow tablets

Keywords: branched-chain amino acids leucine muscle damage inflammation supplementation resistance exercise-induced
evaluating positron emission mammography imaging of suspicious breast abnormalities

Conditions: Breast Cancer

Summary: the goal of this pilot project is to test the new radialis positron emission mammography (r-pem) system in breast cancer patients that has a higher sensitivity with lower radiation doses than conventional pet/ct. the plan for the pilot study is to image patients who are already scheduled for diagnostic imaging for breast cancer after a positive core biopsy. participants will be injected with 5mci (millicurie) of f18-fluorodeoxyglucose (fdg) and patient will wait for a couple of hours for uptake of fdg. after this time, the first r-pem scan will occur. additional optional r-pem scans can be performed 4 hours after injection and 7 hours after injection with reductions in radiation emission. additionally, r-pem images will be compared to standard-of-care breast magnetic resonance imaging (mri) and digital breast tomosynthesis (dbt) to study extension of disease and screening of contralateral breast.


Eligibility criteria:
inclusion criteria: * subject is female of any race and ethnicity * subject is at least 26 years old * following routine mammography imaging, subject is categorized as bi-rads score 4c or 5 because of calcifications, masses, asymmetries or/and architectural distortion will undergo additional tests including biopsy within 30 days of routine imaging * subject is female with a recent breast biopsy confirming breast cancer exclusion criteria: * subject unable or unwilling to undergo informed consent * subjects who are unable or unwilling to tolerate any of the imaging tests because of claustrophobia, compression, etc. * subjects who are pregnant or who think they may be pregnant * subjects who are breast-feeding * subjects weight exceed table limits of mri and pet-ct (300-450 lb or 135-205 kg) * subjects with history of allergic reaction to gadolinium or previous history of life-threatening anaphylactic reaction to any contrast. * claustrophobic subjects
real-world cmv outcomes among kidney transplant recipients in brazil

Conditions: CMV Infection; CMV Viremia

Summary: this is a single-center, non-interventional, retrospective study of data, at the level of the individual without identification, extracted from medical records of adult patients undergoing a kidney transplant procedure after 1st from january 2018 until reaching the sample size enrollment (around 500 individuals); this refers to the period of verification of individuals' eligibility for entry into the study. individuals under strategy preemptive patients who developed cmv infection/disease within 12 months after transplantation. the data will be collected from date of transplant (including pre-transplant clinical history) until completion of at least 12 months after transplantation, or until graft loss, or recipient death or loss to follow-up, when/if applicable.

data will be collected from medical records and will include transplant recipient characteristics, transplant-related information, cmv status, clinical outcomes, treatment patterns, healthcare resource utilization and captured on an electronic intake form. study-specific case report (ecrf) the sponsor will create a statistical analysis plan (sap) before collection begins of data. the ecrf system will comply with research regulations

Eligibility criteria:
inclusion criteria: * received a single kidney transplant after january 1, 2018 * age over 18 years at time of kidney transplant. * it was under preemptive strategy. * diagnosed with cmv infection/disease within the first 12 months after kidney transplant. * follow-up information is available in medical records for at least 12 months after confirmation of cmv infection, or even loss of the allograft, death of the recipient or loss of follow-up of the receiver, when/if applicable. exclusion criteria: * diagnosed as a carrier of the human immunodeficiency virus (hiv+), hepatitis b virus and/or hepatitis c before kidney transplantation. * participation in any interventional study during the period between kidney transplantation and a period of 12 months after cmv diagnosis.